Autopsy report · NCT03448666

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

“no financial support”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

European Institute of Oncology

Sponsor type

University, hospital or other

Conditions

Malignant Melanoma

Interventions

Pembrolizumab

Participants

0

Sites

1

Countries

Italy

Trials that died the same way

• Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer
  “No financial support aproved” (93% match in meaning)
• Nebulized 3% Hypertonic Saline vs. Standard of Care in Patients With Bronchiolitis
  “Lack of financial support” (86% match in meaning)
• IntraDermal Versus Intramuscular Comirnaty® Efficacy Study
  “No financial budget support” (85% match in meaning)
• Patient-derived-organoid (PDO) Guided Versus Conventional Therapy for Advanced Inoperable Abdominal Tumors
  “no funding support” (83% match in meaning)
• FSH Doser for Controlled Ovarian Stimulation
  “Seeking financial support.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.